A phase I single-arm, multicenter pilot study aimed at validating y-OHPdG as a biomarker and testing the effects of Polyphenon E on its levels in patients with cirrhosis

NIH RePORTER · NIH · N01 · $142,069 · view on reporter.nih.gov ↗

Abstract

Hepatocellular carcinoma (HCC) is a lethal cancer with rising incidence and rates. In 2014, about 33,000 HCC diagnoses were expected, and the incidence is increasing among the most rapidly of any cancer, with an age-adjusted annual increase of 3.7% and 2.9% in men and women, respectively (3%). Tragically, HCC has a dismal 5-year survival rate of 18%. Hepatocarcinogenesis begins with changes in the liver architerure as reflected by various degrees of cirrhosis.

Key facts

NIH application ID
10551085
Project number
261201200035I-P00005-26100013-1
Recipient
NORTHWESTERN UNIVERSITY
Principal Investigator
Seema Khan
Activity code
N01
Funding institute
NIH
Fiscal year
2022
Award amount
$142,069
Award type
Project period
2020-11-06 → 2023-09-22